Founder and Chairman
Attila Bérces is a life-science business leader with global experience in scientific research, R&D management, company foundation and start-up development. As a scientist he published 50+ peer-reviewed research publications and delivered 50+ scientific presentations at scientific conferences and work has been cited over 1600 times. As a founder of Omixon he lead the company with strong genomic data analysis skills to the market niche of immunogenetics, developed the business model, led the licensing from the Children’s Hospital of Philadelphia, and thus established the foundation of a first-in-class and best-in-class human leukocyte antigen diagnostic test using next generation DNA sequencing. Omixon is a leader in HLA typing by next generation sequencing today. He is passionate about new molecular diagnostics product development where the challenge involves the combination of IP strategy, licensing, market research, competitive analysis and technology development. He was inspired to pursue entrepreneurship at the National Research Council (Canada), where he experienced the formation of 48 spin-off companies with funding over $300M in the 1990s. In Canada, his research supported a group of scientists whose decade-long effort lead to a carbohydrate vaccine saving lives of children. He believes that there are unexplored opportunities to commercialize great scientific results from academic labs. Currently several academic results in immunotherapy of cancer have great potential.
Chemistry, bioinformatics, business development, genomics, chemistry, drug discovery, drug development